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Background: Long-acting nanoformulated antiretroviral therapy (nanoART) is designed to improve patient regimen
adherence, reduce systemic drug toxicities, and facilitate clearance of human immunodeficiency virus type one (HIV-1)
infection. While nanoART establishes drug depots within recycling and late monocyte-macrophage endosomes,
whether or not this provides a strategic advantage towards viral elimination has not been elucidated.
Results: We applied quantitative SWATH-MS proteomics and cell profiling to nanoparticle atazanavir (nanoATV)-treated
and HIV-1 infected human monocyte-derived macrophages (MDM). Native ATV and uninfected cells served as controls.
Both HIV-1 and nanoATV engaged endolysosomal trafficking for assembly and depot formation, respectively. Notably,
the pathways were deregulated in opposing manners by the virus and the nanoATV, likely by viral clearance.
Paired-sample z-scores, of the proteomic data sets, showed up- and down- regulation of Rab-linked endolysosomal
proteins. NanoART and native ATV treated uninfected cells showed limited effects. The data was confirmed by
Western blot. DAVID and KEGG bioinformatics analyses of proteomic data showed relationships between secretory,
mobility and phagocytic cell functions and virus and particle trafficking.
Conclusions: We posit that modulation of endolysosomal pathways by antiretroviral nanoparticles provides a
strategic path to combat HIV infection.
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Long acting nanoformulated antiretroviral therapy (nanoART)
is emerging as an important part of the treatment
armamentarium for human immunodeficiency virus
type one (HIV-1) infection [1-4]. While our prior studies
defined both a platform for drug delivery and the traffick-
ing mechanisms operative for nanoART in monocyte-
macrophages, how these cells can be harnessed as drug
vehicles for improved antiretroviral responses has not been
realized [5-9]. Indeed, human monocyte-derived macro-
phages (MDM) serve as nanoART carriers extending ART* Correspondence: hegendel@unmc.edu
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unless otherwise stated.half-life and drug stability [10-12]. Such cell-based drug de-
livery strategies may also decrease systemic drug toxicities
[13,14]. We posit that endolysosomal pathways can serve as
Trojan horses for viral persistence or as vehicles for its
elimination. If correct, facilitated viral replication and the
means to eliminate it may occur at identical subcellular
locales. The operative nanoART response would facili-
tate drug delivery by bringing the medicine to the site of
viral replication and assembly within mononuclear
phagocytes (MP; monocytes, macrophages and dendritic
cells). To investigate this apparent mechanistic paradox,
functional proteomic tests were employed to uncover
how drug particles affect the HIV-1 replication cycle be-
yond nanoART activity.
The intracellular trafficking pathways held by the virus
and nanoART were investigated by Sequential Windowed
data independent Acquisition of the Total High-resolutionl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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applied to obtain a broader picture of complex nanoART-
HIV interactions. The method was previously employed in
our laboratory an others to identify and quantify cellular
peptides on a larger scale [15-19]. While past transcrip-
tomic and proteomic analyses were applied to study virus-
cell interactions [16-19], they have failed to uncover key
proteins affected by targeted antiretroviral treatments.
Herein, we identified deregulated cellular proteins affected
by nanoatazanavir (nanoATV) in HIV-1-infected MDM.
Comparison was made between nanoformulated and
native ATV treatments as related to the proteomic
effects induced by HIV-1. Common cellular proteins
with coordinated molecular, biochemical and biological
functions were altered in virus-infected and nanoATV
treated cells. These were linked to phagosome signalling
pathways clearly associated with the endosomal and lyso-
somal compartments. Specifically, opposing expressions of
Rab5 and −7 and LAMP1 were seen in HIV-1 infected and
nanoATV-treated cells. Notably, the downregulation of late
and recycling endosomes and LAMP1 indicated that path-
ways that could be employed, in measure, for viral
assembly and nanoparticle lysosomal degradation were
affected. Through cross validation of proteomics, cell
biology and protein chemistry, our data provide novel
insights into how nanoART facilitates viral clearance
while establishing long-lived cell-based depots different
from native drug. These works represent a previously
unknown mechanism for how long-acting nanoART
provides a strategic advantage to combat viral infection.
Results
Proteomics analyses of HIV-1 infected MDM
HIV-1 infection engages a spectrum of cellular proteins
seen in specialized cell populations that support its repli-
cation [20-23]. The effect of nanoART on cell protein
expression has not yet been defined, in its target macro-
phage. To such ends, we applied quantitative SWATH-
MS proteomics followed by bioinformatics to uncover
proteins deregulated by native ATV or nanoATV with
or without HIV-1 infection. For these experiments
MDM were first infected with HIV-1ADA and four hours
later medium was removed and cells were treated with
100 μM P407-ATV. Following 16 hours of drug treat-
ment, the media was replaced with drug-free fluids and
cells were harvested for proteomic tests after an add-
itional seven days. This experimental paradigm was
followed to assess the role that the antiretroviral delivery
system had on the macrophage proteome during spread-
ing viral infection. To separate the effects of the anti-
retroviral drug, the nanoparticle and the viral infection,
separate and combined analyses of each of these were
required. MDM were infected with HIV-1 at a MOI of
0.1 then treated with 100 μM native- or nanoATV. Afterseven days, cells were harvested and SWATH-MS was
performed on whole cell lysates [15]. Because of the ex-
pansive proteomic data sets and analyses based on the
biological response variables amongst the nanoATV,
ATV and HIV-1 treatments the data are presented in 7
additional files and two figures. Figure 1 illustrates differ-
ences in protein expression between HIV-1 infected cells
with or without nanoART as compared to controls (unin-
fected-untreated MDM) and Figure 2 illustrates differences
in protein expression between uninfected cells treated with
native- and nanoATV compared to controls. Quantitative
profiling identified 527 significantly changed MDM pro-
teins following HIV-1 infection. These were up- or down-
regulated (p < 0.05) and were assessed by paired-samples
z-scores (Additional file 1). The numbers of proteins exhi-
biting changed expression in HIV-1-infected cells were
greater than in replicate infected cells treated with
nanoATV, 527 versus 376 respectively (Additional file 2A).
Up- and down- regulated proteins in HIV-1 infected cells
were 41 and 59% of total (n = 216 and 311, respectively). In
contrast for nanoATV-treated HIV-1-infected MDM, up-
and down-regulated proteins were 59 and 41% of total (n =
222 and 154, respectively). Uninfected cells treated with
nanoATV had fewer deregulated proteins (n = 195) com-
pared to the other groups (Additional file 1). The proteins
uncovered engaged the PANTHER database which sorted
the deregulated proteins by classes. This illustrated the
relative numbers of proteins in each class for the HIV-1-
infected and infected and nanoATV-treated cells
(Additional file 2B). This showed that the number of
deregulated proteins in HIV-1-infected versus infected and
nanoATV-treated cells was greater for each of the classes
(nucleic acid binding, hydrolase, transferase, protease,
signalling molecule, transporter, transcription factors and
ligases). These results demonstrate that the deregulation
of cellular proteins by HIV-1 infection can be altered by
nanoATV treatment. To uncover the function of the
classes of proteins deregulated by HIV infection we ex-
amined the functional categories by PANTHER classifi-
cation. These data are based on Gene Ontology
annotations (GO molecular function, GO biological
processes and GO cellular component). Additional file
3A shows the proteins sorted according to molecular
function with the percentages of total deregulated pro-
teins classified for subgroups. Common proteins were
separated based on binding (28 to 31%), enzyme regula-
tor (5%) and transporter (3-4%) activities between the
nanoATV, HIV-1 and HIV-1 and nanoATV treated
MDM. Proteins included Rab5, −7 (GDP/GTP and pro-
tein binding) and LAMP1 (enzyme and protein bind-
ing). The classification revealed enrichment for
metabolic, cellular, localization, regulation and cellular
organizational cellular processes. These were the princi-
pal categories or protein sets (Additional file 3B). The
Figure 1 (See legend on next page.)
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Figure 1 Schematic representation of the MDM phagosome network identified in HIV-1-infected (A) and HIV-1-infected and nanoATV
treated cells (B). Proteins identified were compared against control uninfected MDM cultures (p < 0.05). The acquired profiles were analyzed through the
bioinformatics program using a comprehensive set of functional annotation tools to uncover biological data sets behind the uncovered list of genes. Data
for Annotation, Visualization and Integrated Discovery (DAVID) facilitated the linked sets of enriched functional-related protein groups. This tool was
employed to identify enriched biological processes among the expressed proteins. Gene Ontology terms were used to identify related pathways with the
assistance of the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. The KEGG database facilitated the elucidation of the functions for the MDM
as derived from the proteomic datasets. Statistical significance was determined using a p-value < 0.05. Proteins in red and blue, display up- and down-
regulation, respectively. Proteins in green belong to the phagosome network and not deregulated by ATV treatment. The differences in protein up- and
down-regulation between HIV infection alone and HIV infection with nanoATV treatment are circled in red.
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groups. GO for cellular component showed that deregu-
lated proteins sorted by cell organelle and macromol-
ecular complex (Additional file 3C). Note that such
groupings were common to HIV-1 and HIV-1 and
nanoATV treated cells. The data demonstrated that
HIV-1 and HIV-1 and nanoATV, as compared to con-
trol, affect similar cellular processes. However, the num-
bers of proteins in each were reduced following
infection and nanoATV treatment.
KEGG pathway analyses for HIV-infected MDM
The proteins relative to functional pathways were further in-
vestigated using the KEGG database, which indicated pha-
gosomes as one of the main pathways related to HIV-1
infection and nanoATV treatment. First we identified the
role of HIV-1 infection as compared to HIV-1 infected
nanoART-treated MDM on the phagosome network
(Figure 1A and B, respectively). Few proteins were deregu-
lated with nanoATV treatment. However, more proteins
were deregulated during HIV-1 infection and nanoATV
treatment. Notably, there was an opposite regulation for
proteins within the phagosome and endosomal compart-
ment between HIV-1-infected and HIV-1-infected and
nanoATV-treated MDM. Up-regulation of Rab5 and −7
proteins was observed in HIV-1 infected cells; in contrast
these same proteins were down-regulated in nanoATV-
treated HIV-1 infected cells (pink = increased expression,
blue = decreased expression). A similar pattern for LAMP1
was also observed. Moreover, DAVID functional enrich-
ment clustering gave similar enrichment results for lyso-
somes in HIV-1-infected and HIV-1-infected and
nanoATV-treated cells by filtering the data sets at a P value
<0.01 (Additional files 4, 5, 6). There was a down-
regulation of endosomal and lysosomal proteins in the un-
infected cells treated with native ATV (Figure 2A) or
nanoATV. The latter showed few down-regulated proteins
in parallel endosomal compartments (Figure 2B). HIV-1
and native ATV treatment was similar to HIV-1 alone (i.e.
high number of altered proteins). There were less numbers
of oppositely regulated proteins compared to HIV and
nanoATV (data not shown). A composite of these protein
network changes are summarized in Figure 3.Protein-protein interaction networks
To elucidate the operative and dynamic biological pro-
cesses, methods depicting changes of protein interaction
networks are needed. Here we used our data from
SWATH-MS and applied it to the STRING bioinformat-
ics tool to determine the dynamics of the protein inter-
action after HIV-1-infection with or without nanoATV
treatment. Differentially expressed proteins in infected
or infected and treated MDM were identified using a
P-value <0.05, and protein-protein interaction networks
were constructed. The results of the networking repro-
duced a consistently high number of altered cellular pro-
teins by HIV-1 (Additional file 7A). The complex changes
and interactions during HIV-1 infection are clearly visual-
ized and, more importantly, the reduced complexity is
clear when the infected cells are treated with nanoATV
(Additional file 7B). These dynamic changes following
HIV-1 infection and nanoATV treatment provide evi-
dence of the importance of antiretroviral therapy to
control protein-protein interaction networks.
Antiretroviral activities of native and nanoformulated ATV
To confirm the antiretroviral activity of nanoATV treat-
ment HIV-1 reverse transcriptase (RT) activity was deter-
mined in HIV-1-infected human monocyte-derived
macrophages (MDM) treated with either native- or
nanoATV. Cells were treated with 10, 100 or 250 μM of
native- or nanoATV for 16 hours. At this time the medium
was removed, cells were washed 3 times with phosphate
buffered saline and fresh medium without drug was added
prior to HIV-1ADA challenge at a multiplicity of infection
(MOI) of 0.1 at days 0, 5 and 10 after treatment. Infected
cells were cultured for an additional 7 days and RT activity
in the culture medium was determined. Significant differ-
ences were found between cells treated with native- or
nanoATV. For native ATV treated cells, RT activity was
suppressed only in the day 0 infection group, at all treat-
ment concentrations. At 10 and 100 μM little antiviral
suppression was observed in the days 5 and 10 infection
groups. In contrast, for cells treated with nanoATV, RT
activity was suppressed to less than 20% HIV-1 positive
control with all treatment concentrations and at all infec-
tion days (Figure 4).
Figure 2 (See legend on next page.)
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Figure 2 Changes in MDM phagosome network for uninfected cells treated with native ATV (A) or nanoATV (B). Proteins were compared
to uninfected and untreated MDM controls (p < 0.05) then bioinformatics analysis performed following parallel procedures described in Figure 1.
Proteins in red and blue, display up- and down- regulation, respectively. Proteins in green belong to the phagosome network but were not
significantly altered by viral infection or treatment.
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We selected the proteins from the KEGG pathway related
to phagosome and endosomal compartment which were
oppositely regulated by HIV-1 and HIV-1/nanoATV, (Rab
5, −7, −11 and LAMP 1), for validation of the proteomics
analysis. Protein expression of Rab 5, −7, −11 and LAMP1
was determined by Western blot. As shown in Figure 5,
there was a down-regulation in Rab 5, −7, −11 and
LAMP1 protein expression in nanoATV-treated infected
cells group. This effect was greater than that seen with
native ATV treatment, validating the KEGG analyses, and
was time dependent; highlighting the dynamic nature of
endosomal trafficking based on macrophage differenti-
ation, viral infection and nanoATV treatments. Notably,
assay of Rab protein levels, at multiple days following of
HIV-1 infection and antiretroviral treatment revealed that
nanoATV while inducing a significant down-regulation of
endosomal and lysosomal proteins the effects paralleled
what was observed in uninfected cells. Moreover, the
downregulation was significant as it was sustained over
10 days. To better assess the potential relationships
between the virus, Rab protein and nanoART we used
immunofluorescence to visualize if co-localization of
Rab7 or LAMP1, HIV-1 p24 and nanoATV could occur.
Immunofluorescence co-localization (Figure 6) demon-
strated that HIV-1 p24 (yellow), Rab7 or LAMP1 cellularFigure 3 Endolysosomal proteins in HIV-1, HIV + nanoATV, nanoATVproteins (red) and nanoATV (green) were in the identical
cellular locale. These results highlight the fact that the
endosomal trafficking routes taken by the virus and the
nanoATV are identical. Most importantly the results sup-
port the idea that HIV-1 and nanoATV while present in
the identical subcellular locale influence endosomal traf-
ficking in opposite ways.
Cytokine profile for HIV-1 and nanoATV
To assess the activation state of the MDM, cytokine pro-
duction was determined in HIV-1 infected cells with or
without nanoATV treatment. Cell culture media from
nanoATV treated and untreated HIV-1 infected and un-
infected MDM were incubated with capture beads for
IL-12, TNF, IL-10, IL-6, IL-1β and IL-8 and a detection
fluorochrome. Acquisition was performed by FACSArray
cytometry. IL-12 and TNF were increased in HIV-1 in-
fected MDM. However, when the infected cells were
treated with nanoATV cytokine levels were reduced
(Figure 7), implying a positive correlation with endosomal
and lysosomal proteins expression in our analysis men-
tioned above. NanoATV treated infected macrophages
also expressed higher levels of IL-6 and IL-8, compared to
infected and uninfected cells. There were no significant
changes for IL-10 and IL-1β (data not shown). These
results showed a negative correlation in the expression ofand native ATV treated MDM.
Figure 4 NanoATV treatment affects HIV-1 reverse transcriptase (RT) activity. HIV-1 RT activity was determined in treated (native ATV or
nanoATV) MDM followed by HIV-1 infection at days 0, 5 or 10. HIV-1 infected cells without any treatment served as a positive control for RT
activity. All samples were collected after 7 days of viral infection. Results shown are the mean of 5 replicates.
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infected MDM, suggesting a role for nanoATV as a regu-
lator of pro-inflammatory cytokines.
Discussion
While it is well known that HIV-1 alters cellular nucleic
acid binding and regulatory protein functions affecting
its transcription and translation [15,24-26] how such
virus-host cell interactions are altered when viral repli-
cation is attenuated by nanoART is not understood [11].
The effect of nanoART alone was also investigated here.
To this end, we used functional proteomics, cell biology
and protein chemistry to investigate potential interac-
tions between the virus, the host cell and nanoART to
elucidate how metabolic and signaling pathways can be
engaged to both support viral replication and, at the
same time, affect its elimination. Endolysosomal path-
ways were uncovered and found to be antagonistic in
HIV-1 infected cells with nanoATV treatment. Notably,
the results highlight how the cell can be manipulated to
either facilitate or inhibit viral growth.
The data also serves to highlight unique cellular pro-
cesses engaged in both the viral replication cycle and the
means to attenuate it. Within an infected cell, virions
are formed in association with the cellular membrane.
Initial investigations of HIV-1 assembly in macrophages
were done through electron microscopy studies and sug-
gested that new virions were formed from the limiting
membrane of a late endosomal compartment that was
linked to vesicle formations as is known to occur in
multi-vesicular bodies (MVB) but not at the plasma
membrane known to be operative in T cells [27]. Thelinkage between Endosomal Sorting Complex Required
for Transport (ESCRT), MVB biogenesis and viral budding
is well known. In past years it was thought that HIV-1 bud-
ding is linked to ESCRT through the presence of late endo-
somal markers associated with macrophage-derived virions.
However, the model has now been re-examined with sev-
eral recent reports showing that the viral compartment has
a neutral pH and can be connected to the plasma mem-
brane by micro-channels [28-33]. We posit that the virion
trafficking and viral budding can be independent but not
mutually exclusive pathways and showed that both are
likely operative. First, we now show through cross valida-
tions of proteomic, cell biology and protein chemistry that
the endolysosomal machinery is significantly deregulated by
HIV-1 infection and in an opposite manner by nanoART
treatment. Second, there is a close association between
endosomal-linked pathways that include Rab5, −7 and −11
and viral infection. Third, the fact that this pathway is con-
versely down regulated by HIV-1 infection likely reflects
that the ability of the virus to hijack ESCRT is augmented
by the drug nanoparticles. Such a theory was previously put
forward in our own past works [11]. In regards to assembly
and intracellular accumulation of progeny HIV-1 we need
not discount the elegant work performed by immunofluor-
escence microscopy and immunoelectron microscopy that
the organelles of an internally sequestered plasma mem-
brane domain are divergent from endosomes. Both path-
ways can be operative in this scenario and are not mutually
exclusive from one another. Nonetheless, there is little
question that virions are endosomal-associated.
Progeny virions are pulled down that are associated
with these proteins and reverse transcriptase activities
Figure 5 NanoATV and HIV-1 endosomal protein regulation.
Western blot of Rab5, −7, −11, LAMP1 and β-actin was performed in
cell lysates from MDM treated with native ATV or nanoATV and
infected with HIV-1 at day 0, 5 or 10 post-drug treatment then
incubated for 7 days. Uninfected cells and infected cells without
drug treatment served as negative and positive controls for differential
expression of cellular proteins during HIV-1 infection. Blots shown are
from one donor and experiment, and equivalent to two independent
experiments performed.
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did not study the tetraspanins CD81, CD9, and CD53,
their regulation in phagocytosis or intracellular trafficking
is appreciated [34]. It is noted that CD81 is linked to acti-
vation of mononuclear phagocytes, notably microglia [35].
Moreover, they are also involved in the formation of mul-
tinucleated giant cells [36] an additional major feature
of viral infection in macrophages. Rab proteins func-
tion to evade degradation and direct transport to intracel-
lular locations and utilize host vesicles to affect a stable
intracellular niche for microbial stability and longevity
[37]. Thus, it is not surprising that HIV-1 would induce
the Rab pathways. While in uninfected macrophages theproteins are at the cell surface and in intracellular
vacuole-like structures with a complex content of vesicles
and interconnected membranes, these compartments are
in a dynamic state within the cell and strongly regulated
by HIV-1. While we acknowledge that endosome markers
could be recruited to the viral structures and incorpo-
rated into virions the dynamic process of the virus and
the macrophage transcends progeny virion assembly
and includes viral trafficking and transport mechanisms.
Such observations combined with a broader theory of the
complexity of virus-cell interactions in the infected mac-
rophages heralds the notion that multiple events are op-
erative for virion assembly and persistence [38].
NanoART enters the macrophages primarily through
clathrin-mediated pathways and is then stored in endocy-
tic compartments. This provides a protected environment
for release of the drug to sites of viral growth. Compared
with nanoART, the non-formulated native drug didn’t
show similar trafficking behavior since less endolysosomal
proteins were found related to native drug treatment. On
the one hand, amorphous native drug can hardly be taken
or stored by macrophage; however, native drug cannot be
internalized or carried by subcellular compartments for
intracellular transportation. Subcellular distribution of
nanoformulated ART is in late and recycling endosomal
compartments. These same compartments serve as drug
depots. Since late endosomes are sites of viral assembly,
nanoART stored within such compartments can retain
significant antiretroviral activity. This was clearly demon-
strated by the significant reductions in HIV-1 RT activity
previously observed in isolated endosomal compartments
in nanoATV treated HIV-1 infected MDM.
All together, the current studies suggest a mechanism
whereby the endolysosomal pathway is harnessed for
HIV-1 viral replication and this same pathway may
provide a means for its elimination. Indeed, while it is
known that HIV-1 traffics through Rab5, −7, and −11
endosomal compartments how such early, late, and
recycling endosomal pools regulate stages of the viral
life cycle are not understood [39]. Such an intersection
though is believed critical to the viral life cycle as the
functions of the compartments serve to maintain cell
homeostasis and protein transport [40]. It has been
reported that Rab5 regulates clathrin-mediated endocyto-
sis from the plasma membrane to early endosome pools
and serves as an intersection point for proteins sorted to
undergo degradation through Rab7-dependent late endo-
some and lysosomal routes or be sorted back to the
plasma membrane through Rab11-dependent recycling
pathways [39]. The ability of the macrophage to over-
come such degradation events at the subcellular level
underlie its abilities to persistent in its macrophage
reservoir [39]. Moreover, it is well known and accepted
that Rab proteins function to evade degradation and
Figure 6 (See legend on next page.)
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Figure 6 Subcellular localization of nanoATV, HIV-1 and endolysosomal proteins. Cellular localization of Rab7 or LAMP1 endosomal
compartments (red), HIV-1p24 (yellow) and nanoATV (green) are shown by confocal microscopy. Cell nuclei were stained with DAPI (blue).
Merged images showed the co-localization of all proteins. Fluorescence images were acquired with a LSM 510 confocal microscopy,
400x magnification.
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host vesicles to affect a stable intracellular niche for
microbial stability and longevity. Similar mechanisms
certainly parallel the persistence of nanoART and sus-
tained drug depots for extended time periods. Notably,
proteomic tests revealed a large number of proteins
deregulated by HIV-1 infection and these were the
same protein sets also affected by nanoART. The pro-
tein sets included those affecting nucleic acid binding,
hydrolase and enzyme activities, oxidoreductase re-
sponses, and the cellular cytoskeletal backbone. These
were all characterized by GO molecular function that
placed Rab5 and −7 proteins as those engaged in GTP
catabolic processes, endocytosis and small GTPase-Figure 7 NanoATV regulation of cytokine profiles in HIV-1 infected M
infected with HIV-1 at day 0, 5 or 10 post-drug treatment. Untreated, uninf
culture media were collected and analyzed using a cytokine bead array. (A
for control, treated, HIV-1 infected and treated infected MDM. Cytokine lev
FlowJo (version 10.7) software. (B) Levels of IL-12 and TNF after treatment
values of cytokine expression were expressed as pg/mL.mediated signal transduction pathways. The molecular
functions for both endosomal-linked proteins are GDP/
GTPase activity and protein binding [41]. LAMP1 is
associated with autophagy, the establishment of protein
localization to cell organelles, golgi to lysosome trans-
port, protein transport along microtubules and regulation
of natural killer cell degranulation cytotoxic activities.
For the cellular component GO classification, LAMP1
is located at the late endosome, lysosome, multivesicu-
lar body and vesicular exosome. It is included in the
group of enzyme and protein binding molecular function
protein sets. Indeed, as described by GO information, Rab
family members are small, RAS-related GTP-binding
proteins that regulate vesicular transport. Each Rab targetsDM. MDM were treated with 100 μM native ATV or nanoATV and
ected cells were used as controls. After 24 hours of viral infection, cell
) Density plots show expression of IL-12, TNF, IL-10, IL-6, IL-1β and IL-8
els were detected by FACSArray cytometer and data was plotted using
and infection are shown. Data are analyzed using FCAP software and
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pathways.
An important finding in the current study was that
Rab5, −7 and −11 and LAMP1 were significantly upreg-
ulated in expression following HIV-1 infection. HIV-1
could induce those proteins linked to endosomes. While
endosome markers could be recruited to the viral struc-
tures and incorporated into virions, the dynamic process of
the virus and the macrophage transcends progeny virion as-
sembly but also viral trafficking and transport mechanisms
also strongly affected during the dynamic course of viral in-
fection. Interestingly, Rab 5, −7, −11 and LAMP1 deregula-
tion in infected MDM was reversed, in part, by nanoATV.
The extent of protein deregulation in infected MDM was
reduced by nanoATV. As shown in some studies, Rab5 has
a role in endocytosis and post-endocytic trafficking [42]. Its
activation promotes focal adhesion disassembly, migration
and invasiveness in tumor cells [43] and its knockdown de-
creases cell motility and invasion by an integrin-mediated
signaling pathway [44]. Moreover, it has been indicated that
Rab5, −7 and −11, affect RGS4 trafficking through plasma
membrane recycling or endosomes [41] and are used by
the drug particles and the virus in a coordinated manner.
This was seen for other viral infections such as hepatitis B
virus, which can affect Rab5 and −7 expressions and use
pathways for viral transport from early to mature endo-
somes. This is a required step in the viral life cycle [45].
Similarly, in our study, following endocytosis HIV-1 travels
through the complex endocytic pathway networks to reach
the nucleus and initiate its replication and as such support
the notion that endosomal proteins play a critical role in
the viral life cycle.
Interestingly, Rab5, −7 and −11 and LAMP1 were
down-regulated in HIV-1 and nanoATV-treated cells.
This opposite regulation between HIV-1 and nanoATV
in regulation of endosomal proteins is likely important
in that cellular trafficking pathways may also be involved
in the release of infectious progeny virus. As such late
endosome-associated Rab7A is known to be required for
HIV-1 propagation, regulation of Env processing and the
incorporation of mature Env glycoproteins into viral par-
ticle [46]. In addition Rab7A promotes Vpu interaction
with BST2/tetherin to facilitate HIV-1 release [47]. This
may also be operative for nanoparticle viral interactions
and suggests that in the present study nanoATV may dis-
rupt mechanisms of critical cellular protein-protein inter-
actions harnessed during the viral life cycle to perpetuate
its growth. In other studies, silencing the expression of
Rab9 inhibited HIV-replication [48] and silencing the
endogenous Rab11a GTPase expression could destabilize
HIV-1 Gag and reduce virion production both in vitro
and in NOD/SCID/γc−/− mice [49]. It has been well
documented that Rab11 is located on pericentriolar recyc-
ling endosomes and plays a key role in regulating vesicletrafficking through recycling endosomes to the plasma
membrane as well as in exocytosis [11,50,51]. Therefore,
down regulation of Rab11, as shown in our study, could
destabilize HIV-1 proteins that would fail to traffic through
the endosomal compartments and could be redirected for
degradation at the lysosomal site.
The deregulation of endosomal proteins suggests a new
mechanism for viral suppression by nanoART. This in-
cludes altered expression of endosomal proteins resulting
in parallel reductions in viral assembly sites. In addition,
reduction of LAMP1 following nanoART treatment could
reduce degradation of the nanoparticles and therefore
extend the half-life of ART. Our data is corroborated by
studies demonstrating co-localization of HIV-1 and
endosomal and lysosomal proteins (Rab7 and LAMP1)
[11,52,53]. Moreover, differences in cytokine profile ex-
pressions in untreated and nanoATV treated infected
HIV-1 macrophages suggest that nanoATV down regu-
lated the expression of pro-inflammatory cytokines. HIV-1
has been linked to the up-regulation of cytokines and in
fact HIV-1 Tat upregulates IL-12 and TNF-α and -β
expression in monocyte-derived dendritic cells [54,55],
suggesting an advantage of nanoATV in the regulation of
pro-inflammatory cytokines during HIV-1 infection. In
contrast with nanoATV, the effect of native ATV was rela-
tively lesser. Moreover, it has been reported that IL-12 up-
regulates Rab7 and induces lysosomal transport. Others
have reported that Rab proteins are regulated by cyto-
kines and affect TNF secretion by activated macro-
phages [56-58]. These findings provide further support
to link Rab, IL-12 and TNF expression. As HIV-1 virions
assemble at the plasma membrane and recruit endosomes
to enable particle release, nanoATV depletes endosomal/
lysosomal proteins and deregulates pro-inflammatory cy-
tokines thus controlling viral growth. Although a mechan-
ism is now forged to bridge nanoATV activities and
endosomal signaling pathways this study serves as only an
entry to future investigations.
To this end, we are currently examining the possible
signaling pathways deregulated by nanoATV. Altogether, we
found that SWATH-MS proteomics, bioinformatics ana-
lyses and cell biology showed that nanoATV treatment of
HIV-infected MDM can down-regulate the endocytic pro-
teins in HIV-1 infected cells and thus decrease the subcellu-
lar space available for viral assembly. Through this
mechanism, nanoATV has unique but real potential to-
wards improving virus clearance. Our work articulates com-
monly used pathways that are engaged in common
macrophage functions such as phagocytosis and vesicular
trafficking that are used both by the virus and the anti-virus.
Conclusion
HIV-1 and nanoATV deregulate cellular proteins in oppos-
ing manners. The common pathways are linked to viral
Araínga et al. Retrovirology  (2015) 12:5 Page 12 of 15assembly and are endolysosomal-linked. Rab5, -7, -11 and
LAMP1 serve to coordinate molecular and biological
functions of the virus and the antivirus in subcellular
compartments. Alterations made by HIV-1 and nanoATV
indicate that specific organelles are action sites for both.
These findings provide novel insights into the role played




ATV sulfate (Gyma Laboratories of America Inc., Westbury,
NY, USA) was free based with triethylamine. Poloxamer
407 (P407) and CF568-succinimidyl ester (CF568) were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Human serum was obtained from Innovative Biologics
(Herndon, VA, USA). Macrophage colony-stimulating
factor (MCSF) was prepared from 5/9 m alpha3-18
cells (ATCC; CRL-10154) [59]. Rabbit anti-human Rab
5, −7, −11, LAMP1 and β-actin antibodies were pur-
chased from Santa Cruz Biotechnology, Dallas, TX,
USA. Alexa Fluor 594 goat anti-rabbit IgG and Alexa
Fluor 647 donkey anti-mouse IgG were obtained from
Life Technologies (Eugene, OR, USA).
NanoATV manufacture and particle characterization
P407-ATV was prepared by high-pressure homogenization
using an Avestin Emulsiflex C3 homogenizer (Avestin Inc;
Ottawa, ON, Canada) [8,60]. CF568-labeled P407-ATV
was prepared as described previously [14] using a 1: 4
(w/w) ratio of CF568-P407 and P407. Drug content of
the nanosuspensions were determined by reverse phase
high-performance liquid chromatography (HPLC) [60].
Particle size, polydispersity and zeta potential for the
nanoparticles were determined by dynamic light scattering
using a Malvern Zetasizer Nano-ZS instrument (Malvern
Instruments Inc.; Westborough, MA, USA).
Monocyte isolation, cultivation and HIV-1 Infection
Human peripheral blood monocytes were obtained by
leukapheresis from HIV-1,2 and hepatitis B seronegative
donors and plated at a density of 1 × 106 cells/mL in
Dulbecco’s modified Eagle’s medium supplemented
with 10% heat-inactivated human serum, 1% glutam-
ine, 50 μg/ml gentamicin, 10 μg/ml ciprofloxacin and
1,000 U/ml MCSF [61]. After seven days of cell differ-
entiation, MDM were infected with HIV-1ADA at a
MOI of 0.1 infectious viral particles per cell. After
4 hours the medium was removed and cells were
treated with 100 μM native- or nanoATV. Following
16 hours of drug treatment, the media was replaced
with drug-free fluids and cells were incubated for an
additional seven days [9].SWATH-MS
MDM samples for mass spectrometry were collected
seven days after infection and drug treatment. Cells were
washed with ice-cold PBS, scraped, pelleted, and stored
at −80°C until processed. Cell samples from four donors
were processed simultaneously. Cell pellets were re-
suspended in cell lysis buffer containing 4% (w/v) SDS,
0.1 M dithiothreitol (DTT) and 0.1 M Tris–HCl. Lysates
were vortexed at room temperature for 10 min and then
boiled at 95°C for 5 min to denature proteins. Protein
quantification was performed using the Pierce 660 nm
protein assay (Thermo Scientific; Wilmington, DE, USA)
following the manufacturer’s protocol. On the basis of
protein quantifications, 100–200 μg of each sample was
processed using filter aided sample preparation (FASP)
[62-64]. Samples were denatured with urea exchange
buffer (8 M urea, 0.1 Tris–HCl, pH 8.5) placed into filter
cartridges (10 kDa), centrifuged and then treated with
50 mM iodoacetamide (Sigma-Aldrich). Trypsin (Promega;
Madison, WI, USA) was added (2 μg/100 μg protein) and
incubated at 37°C overnight on the cartridge. Eluted pep-
tides were dried via vacuum centrifugation. Peptides were
cleaned using an Oasis mixed cation exchange cartridge
following manufacturer’s protocols (Waters Inc.; Milford,
MA, USA) and then dried under vacuum. After processing
through mixed cation exchange, peptides were subjected to
further clean up using C18 Zip-Tips (EMD Millipore;
Billerica, MA, USA) and dried under vacuum. Pep-
tides were resuspended in 0.1% formic acid (Honeywell
Burdick & Jackson; Muskegon, MI, USA) and quantified
using NanoDrop2000 (Thermo Scientific). One μg of
peptide was then prepared for SWATH-MS quantitative
proteomics analysis, as previously described [15,65].
Samples used to generate the SWATH-MS spectral library
were subjected to traditional, data-dependent acquisition
(DDA).
Bioinformatics
Each SWATH-MS condition (per each donor) was
transformed independently of other conditions and
comparisons between control condition and experimental
conditions were calculated. Extracted raw data transform-
ation was performed as described by Haverland et al. [15]
The raw intensity for each protein was transformed by
taking the natural log (ln) of the intensity followed by as-
signment of z-score. The p-value for the computed z-score
was assigned using standard normal distribution. Func-
tional analysis and signalling pathway representation were
performed using an array of complementary, open-access
bioinformatic tools. Functional annotation of the proteins
differentially expressed was performed using the Database
for Annotation, Visualization and Integrated Discovery
(DAVID) Bioinformatics Resources (6.7) and the Protein
Analysis Through Evolutionary Relationships (PANTHER)
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quence feature. The gene ontology (GO) annotations
showed proteins according to Biological Processes,
Molecular Functions and Cellular Components. Protein
class functional analysis was obtained by PANTHER. Pro-
tein–protein interactions among all identified transcrip-
tion regulators were investigated using Search Tool for the
Retrieval of Interacting Genes/Proteins (STRING) (9.1)
considering a confidence of greater than 0.4 (medium
confidence). Unconnected proteins (orphan proteins) and
unconnected satellite networks (networks which were de-
tached from the largest network) were removed.
The complementary pathway analysis, Kyoto Encyclopedia
of Genes and Genomes (KEGG) was used to determine
significant pathways between experimental conditions.
The KEGG pathway (71.0) for the phagosome was
coloured using the KEGG mapper colour pathway tool.
Green represents all proteins confidently identified
and red and blue colors are assigned to up- or down-
regulated proteins, respectively.
Antiretroviral activities
HIV-1 reverse transcriptase (RT) activity was measured
to assess antiretroviral efficacy in HIV-1 infected MDM.
MDM were treated with 10, 100 or 250 μM native- or
nanoATV for 16 hours then infected with HIV-1ADA for
4 hours at a MOI of 0.1 immediately and five and 10 days
after drug treatment. Following viral infection, cells were
cultured for an additional seven days at which time cell
media were collected for measurement of RT activity
[7,9]. Briefly, in a 96-well plate, 10 μL of sample super-
natants were mixed with 10 μL of solution containing
100 mM Tris–HCl (pH 7.9), 300 mM KCl, 100 mM
dithiothreitol, 0.1% NP-40 and water. The reaction mix-
ture was incubated at 37°C for 15 min and 25 μL of a solu-
tion containing 50 mM Tris–HCl (pH 7.9), 150 mM KCl,
5 mM DTT, 15 mM MgCl2, 0.05% NP-40, 10 μL/mL poly
(A), 0.25 U/mL oligo d(T) and 10 μCi/mL 3H-thymidine
triphosphate was added to each well; plates were incu-
bated at 37°C for 18 hours. Following incubation, 50 μL of
cold 10% TCA was added to each well, the wells were
harvested onto glass microfiber filters and the filters
were assessed for 3H-thymidine triphosphate incorpor-
ation by β-scintillation spectroscopy using a TopCount
NXT (Perkin Elmer Inc.; Waltham, MA, USA).
Western blots
Protein expressions of Rab 5, 7 and 11, LAMP-1 and
Actin were detected by Western blot assays. MDM were
treated with native drug or nanoATV and infected with
HIV-1ADA as described. Seven days after infection cells
were collected and lysed using CellLytic M Cell Lysis
Reagent (Sigma-Aldrich). Protein content was quanti-
tated using the Pierce 660-nm protein assay. Ten μg ofprotein was separated by electrophoresis using a NuPAGE
Novex 4-12% Bis-Tris gel (Life Technologies-Novex;
Grand Island, NY, USA). After electrophoresis, the pro-
teins were transferred to a PVDF membrane (BioRad
Laboratories, Hercules, CA, USA) and then blocked
with 5% non-fat dry milk in PBS and 0.1% Tween-20
(PBST). Membranes were probed with primary anti-
bodies for Rab5, Rab7, Rab11 or LAMP-1 and β-actin
(Santa Cruz Biotechnology) followed by horseradish
peroxidase-conjugated secondary antibody (Life Technolo-
gies-Novex). Proteins were detected using the SuperSignal
West Pico Chemiluminescent substrate kit (Thermo
Scientific) [7,11,66].
Immunofluorescence and confocal microscopy
For immunofluorescence staining, cells were washed
three times with PBS and fixed with 4% paraformalde-
hyde (PFA) at room temperature for 30 min. Fixed cells
were permeabilized with 0.1% Triton in PBS and then
blocked with 5% bovine serum albumin (BSA) in PBS
for 30 min. Cells were washed with 5% BSA in PBS and
sequentially incubated with primary antibodies against
HIV-1 p24 (Dako; Carpinteria, CA, USA) and either
Rab5, −7, −11 or LAMP-1 (Santa Cruz Biotechnology)
for 1 hour then washed 3 times with PBS. Secondary
antibodies conjugated with Alexa594 or Alexa647 dyes
(Life Technologies-Molecular Probes) were applied against
the primary antibody isotype and incubated at room
temperature for 1 hour then washed 3 times with PBS.
Slides were covered in ProLong Gold AntiFade reagent
with DAPI (Life Technologies-Molecular Probes) and
imaged using a 40X oil lens on a LSM 510 confocal
microscope (Carl Zeiss Microimaging, Inc.; Dublin, CA,
USA) [7,67].
Cytokine bead array
MDM were infected with HIV-1ADA for 4 hours at a
MOI of 0.1 then treated with 100 μM native- or
nanoATV for 16 hours immediately. 24 hours after
drug treatment, 50 μL cell culture media from treated
and infected MDM were tested to determine the con-
centrations of inflammatory cytokines measured by a
cytokine bead array (CBA) detection kit (Becton Dickinson
Biosciences; Mississauga, ON, USA) and performed ac-
cording to instructions of the manufacturer. Monoclonal
antibodies specific to interleukin-12 (IL-12), tumor necro-
sis factor (TNF), IL-10, IL-6, IL-1β and IL-8 were added
to the samples in a 96 well plate. A serial dilution of
known cytokines generated the standard curve. Following
three hours of incubation, all samples were acquired and
analysed on a FACSArray. The standard curve was deter-
mined using a parameter logistics model and analysed
with FCAP Array software. Cytokine levels are expressed
as pg/mL [68].
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